DXCM

SEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 3

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,377

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,960

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,946

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 4

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,101

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 3

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,888

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 2

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,285

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,935

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000076 · edgardoc.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,482

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 57,885 unvested restricted stock units. 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 36,116 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

SEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,908

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,898

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,303

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000074 · edgardoc.xml · nonDerivative · entry 3

Abbey Donald · CIK 0001534342 · EVP Global Business Services I

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,023

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000074 · edgardoc.xml · nonDerivative · entry 2

Abbey Donald · CIK 0001534342 · EVP Global Business Services I

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,413

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000074 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP Global Business Services I

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,088

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000061 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP Global Business Services I

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,692

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000060 · edgardoc.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,294

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 57,885 unvested restricted stock units. 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 36,116 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

SEC source: 0001093557-23-000059 · edgardoc.xml · nonDerivative · entry 1

Regan Barry J. · CIK 0001746313 · EVP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,162

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 62,632 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-23-000058 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,759

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000057 · edgardoc.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,305

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000056 · edgardoc.xml · nonDerivative · entry 1

Flynn Paul R · CIK 0001850141 · EVP Global Revenue

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,520

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000055 · edgardoc.xml · nonDerivative · entry 1

Lawver Teri L · CIK 0001960596 · EVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,352

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in four equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 45,352 unvested restricted stock units, 45,352 of which were granted on March 8, 2023 and shall vest through March 8, 2027.

SEC source: 0001093557-23-000054 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306,486

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000053 · edgardoc.xml · nonDerivative · entry 1

Naganathan Girish · CIK 0001949138 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,225

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 50,225 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 31,449 of which were granted on November 8, 2022 and shall vest through November 8, 2026.

SEC source: 0001093557-23-000051 · edgardoc.xml · nonDerivative · entry 1

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,984

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 26,736 unvested restricted stock units, 10,885 of which were granted on March 8, 2023 and shall all vest on March 8, 2026, 4,051 of which were granted on September 8, 2022 and shall all vest on September 8, 2023, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000052 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,240

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000050 · edgardoc.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,153

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-23-000049 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,729

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

SEC source: 0001093557-23-000034 · edgardoc.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,089

F1 · shares: On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $114.79 to $115.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 73,448 unvested restricted stock units, 26,964 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 19,120 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 15,664 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000034 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,808

F1 · shares: On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $113.77 to $114.755. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 73,448 unvested restricted stock units, 26,964 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 19,120 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 15,664 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000033 · edgardoc.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,536

F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000030 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,337

F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $110.31 to $110.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000030 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,598

F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $109.41 to $110.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000028 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,464

F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000026 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,837

F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 54,332 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000016 · edgardoc.xml · nonDerivative · entry 1

Regan Barry J. · CIK 0001746313 · EVP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,386

F1 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 57,172 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-23-000015 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,801

F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $106.50 to $106.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000015 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,952

F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $105.521 to $106.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000011 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,876

F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000012 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 426,645

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-23-000008 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 472,252

F3 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2020 that vested on January 18, 2023, with the applicable performance achieved.

F3 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2020 that vested on January 18, 2023, with the applicable performance achieved.

F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000183 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,288

F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000181 · edgardoc.xml · nonDerivative · entry 1

Flynn Paul R · CIK 0001850141 · EVP Global Revenue

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,744

F1 · shares: On September 9, 2022, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 55,744 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 15,024 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000179 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,237

F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 54,332 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000178 · edgardoc.xml · nonDerivative · entry 1

Regan Barry J. · CIK 0001746313 · EVP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,599

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 57,172 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-22-000177 · edgardoc.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,384

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 59,312 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 15,024 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-22-000173 · edgardoc.xml · nonDerivative · entry 1

Naganathan Girish · CIK 0001949138 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,449

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in four equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 31,449 unvested restricted stock units, 31,449 of which were granted on November 8, 2022 and shall vest through November 8, 2026.

SEC source: 0001093557-23-000008 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,532

F1 · shares: The transaction represents a gift by the Reporting Person of 10,000 shares to a charitable donor advised fund.

F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000157 · edgardoc.xml · nonDerivative · entry 1

Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,942

F1 · shares: This RSU Award was granted pursuant to the Amended and Restated 2015 Equity Incentive Plan, in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 31,107 unvested restricted stock units, 4,051 of which were granted on September 8, 2022 and shall all vest on September 8, 2023, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000155 · edgardoc.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,536

F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000153 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,700

F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.